RNL warns BioArts for patent infringement as its first patent right exercise
Korea, Republic of (Press Release) June 25, 2008 --
RNL Bio Co, Ltd, (RNL) reaffirmed that they were granted the exclusive license for dog cloning from Seoul National University (SNU). The licensing agreement signed early this month, between the two organizations, granted RNL the worldwide rights to clone dogs.
The firm also plans to pursue available legal action against BioArts International Ltd (BioArts) and its affiliate, Sooam Biotech Research Foundation (Sooam) for patent infringement relating to its plan to conduct an online auction for cloned dogs scheduled for July, 2008.
An official from RNL Bio said that they sent a warning letter to BioArts stating that it has no rights to offer such a commercial dog cloning service.
RNL confirms that the only firm authorized to clone dogs (worldwide) is RNL Bio and any entity that wants to access such technology should license the rights from them. Bioarts’ patented technology is related to sheep cloning and has never been able to clone a dog for several years and tens of millions of dollars. RNL also warns Mr. Hawthorne to retract the misleading statements that he has released to media outlets in order to distort RNL’s legal rights, and warns of repetition.
RNL has requested BioArts to respond no later than Jun 30, 2008.
About RNL Bio, CO, LTD.
RNL is a premier biotechnology company in Korea focused on stem cell therapeutics and life sciences technologies. Headquartered in Seoul, Korea with a recently opened state-of-the-art GMP facility, RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and strives to become a global leader in the development of stem cell therapeutics. In early 2008, RNL agreed to collaborate with Seoul National University's Veterinary Medical Teaching Hospital (VMTH), for cell therapeutics and animal cloning.
Contact: RNL Bio 82-2-874-0686 Extention 202 or 206
The firm also plans to pursue available legal action against BioArts International Ltd (BioArts) and its affiliate, Sooam Biotech Research Foundation (Sooam) for patent infringement relating to its plan to conduct an online auction for cloned dogs scheduled for July, 2008.
An official from RNL Bio said that they sent a warning letter to BioArts stating that it has no rights to offer such a commercial dog cloning service.
RNL confirms that the only firm authorized to clone dogs (worldwide) is RNL Bio and any entity that wants to access such technology should license the rights from them. Bioarts’ patented technology is related to sheep cloning and has never been able to clone a dog for several years and tens of millions of dollars. RNL also warns Mr. Hawthorne to retract the misleading statements that he has released to media outlets in order to distort RNL’s legal rights, and warns of repetition.
RNL has requested BioArts to respond no later than Jun 30, 2008.
About RNL Bio, CO, LTD.
RNL is a premier biotechnology company in Korea focused on stem cell therapeutics and life sciences technologies. Headquartered in Seoul, Korea with a recently opened state-of-the-art GMP facility, RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and strives to become a global leader in the development of stem cell therapeutics. In early 2008, RNL agreed to collaborate with Seoul National University's Veterinary Medical Teaching Hospital (VMTH), for cell therapeutics and animal cloning.
Contact: RNL Bio 82-2-874-0686 Extention 202 or 206
Email
Print
Download
SPAM
LEAVE A COMMENT
